Rasna Therapeutics Valuation
| RASP Stock | USD 0 0.00 0.00% |
Rasna Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Rasna Therapeutics from analyzing the company fundamentals such as Return On Equity of -2.94, shares outstanding of 771.81 M, and Price To Book of 0.31 X as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Rasna Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Rasna Therapeutics is based on 3 months time horizon. Increasing Rasna Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Rasna Therapeutics' intrinsic value may or may not be the same as its current market price of 0, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.004 | Real 0.00336 | Hype 0.004 |
The intrinsic value of Rasna Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rasna Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rasna Therapeutics helps investors to forecast how Rasna pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rasna Therapeutics more accurately as focusing exclusively on Rasna Therapeutics' fundamentals will not take into account other important factors: Rasna Therapeutics Total Value Analysis
Rasna Therapeutics is at this time projected to have valuation of 1.22 M with market capitalization of 12.04 M, debt of 91.97 K, and cash on hands of 10.52 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rasna Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.22 M | 12.04 M | 91.97 K | 10.52 K |
Rasna Therapeutics Asset Utilization
One of the ways to look at asset utilization of Rasna is to check how much profit was generated for every dollar of assets it reports. Rasna Therapeutics holds a negative application of assets of -3.7 pct., losing $0.037 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rasna Therapeutics shows how discouraging it operates for each dollar spent on its assets.Rasna Therapeutics Ownership Allocation
Rasna Therapeutics owns a total of 771.81 Million outstanding shares. Rasna Therapeutics holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 85.1 pct. of Rasna Therapeutics outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rasna Therapeutics Profitability Analysis
Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0.About Rasna Therapeutics Valuation
The pink sheet valuation mechanism determines Rasna Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Rasna Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rasna Therapeutics. We calculate exposure to Rasna Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rasna Therapeutics's related companies.Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Rasna Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rasna Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rasna Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rasna Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rasna Therapeutics' revenue streams: Identify Rasna Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rasna Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rasna Therapeutics' growth potential: Evaluate Rasna Therapeutics' management, business model, and growth potential.
- Determine Rasna Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rasna Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Rasna Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rasna Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 111.4 M | |
| Retained Earnings | -24.2 M |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.